Arndt Vogel from/X
Feb 25, 2024, 15:01
Arndt Vogel: Impressive and comprehensive review on BRAF mutations
Arndt Vogel shared on X/Twitter:
“BRAF — a tumor-agnostic drug target with lineage-specific dependencies.
Impressive and comprehensive review on BRAF mutations:
- RAF inhibitor paradox,
- New combinations,
- Overcoming resistance.”
Proceed to the article.
Source: Arndt Vogel/X
Arndt Vogel is a managing senior consultant and professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. He is the Head of the GI-Cancer Center and of the Center for Personalized Medicine at Medical School Hannover and chairs the Hepatobiliary Cancer Study Group of the AIO, a collaborative group in clinical oncology in Germany. His scientific focus is translational and clinical research in gastrointestinal cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 08:59
Nov 13, 2024, 08:39